Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients

NCT03489551 is registered in ClinicalTrials.gov with Michelle Weckmann as lead sponsor.

NCT NCT03489551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03489551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients
Lead sponsor
Michelle Weckmann
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2011
Completion date
October 31, 2013
Enrollment
17 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

delirium, stem cell transplant complications